Anixa Partners with Cleveland Clinic to Take Breast Cancer Vaccine to Human Trials

Anixa Partners with Cleveland Clinic to Take Breast Cancer Vaccine to Human Trials
Anixa Biosciences, a leading company developing anti-cancer immunotherapies, is partnering with the Cleveland Clinic to advance a vaccine against triple-negative breast cancer (TNBC) to testing in humans. "We are pleased to be able to work with Anixa to advance this technology into human trials," Cleveland Clinic researcher Vincent Tuohy, PhD, said in a press release. "The field of cancer therapy has focused on treating patients after they have contracted cancer. If we could vaccinate patients and never allow the cancer to develop, the impact would be immense for patients and our healthcare system.” As people age, certain tissue-specific proteins are no longer needed and stop being produced, i.e., become “retired.” However, these proteins might reappear in tumors, and at even higher levels. Alpha-lactalbumin is one example of a “retired” protein, since its expression is confined to the breast and appears for a limited period of time, during late pregnancy and lactation. The protein is found at high levels in human milk and plays a key role in milk production. However, it is also found at high levels in most cases of TNBC, the most aggressive and lethal form of breast cancer. Tuohy and his team hypothesized that a vaccine targeting the alpha-lactalbumin could help prevent breas
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.